SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-021985
Filing Date
2024-05-09
Accepted
2024-05-09 09:00:09
Documents
70
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mrsn-20240331.htm   iXBRL 10-Q 1194405
2 EX-31.1 exhibit31110-qfy2024q1.htm EX-31.1 11096
3 EX-31.2 exhibit31210-qfy2024q1.htm EX-31.2 11096
4 EX-32.1 exhibit32110-qfy2024q1.htm EX-32.1 5716
  Complete submission text file 0001628280-24-021985.txt   5458314

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrsn-20240331.xsd EX-101.SCH 37048
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrsn-20240331_cal.xml EX-101.CAL 47853
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrsn-20240331_def.xml EX-101.DEF 150937
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrsn-20240331_lab.xml EX-101.LAB 499642
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrsn-20240331_pre.xml EX-101.PRE 355441
74 EXTRACTED XBRL INSTANCE DOCUMENT mrsn-20240331_htm.xml XML 584648
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38129 | Film No.: 24928839
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)